Targets › NDNF
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2028.
Secretory protein that plays a role in various cellular processes. Acts as a chemorepellent acting on gonadotropin-releasing hormone (GnRH) expressing neurons regulating their migration to the hypothalamus. (UniProt, Q8TB73)
Open in Phaseline: the race on NDNF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ruijin Hospital | NTF001 Injection AAV-mediated gene therapy expressing human neuron-derived neurotrophic factor (NDNF) | NDNF | Phase 1 | ALS - Amyotrophic Lateral Sclerosis | Mar 2028 |
ALS - Amyotrophic Lateral Sclerosis (1)
other (1)
Ruijin Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.